Quetiapine Fumarate

Names

[ CAS No. ]:
111974-72-2

[ Name ]:
Quetiapine Fumarate

[Synonym ]:
MFCD03423782
2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate
Quetiapine Hemifumarate
2-{2-[4-(Dibenzo[b,f][1,4]thiazepin-11-yl)-1-piperazinyl]ethoxy}ethanol 2-butenedioate (2:1)
Quetiapine fumarate
Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, 2-butenedioate (2:1) (salt)
Quetiapine hemifumarate salt
Quetiapine (fumarate)

Biological Activity

[Description]:

Quetiapine fumarate is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.IC50 value: Target: 5-HT ReceptorQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor

Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

[References]

[1]. Sheehan DV, Locklear J, Sveds?ter H, Datto C. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. Int Clin Psychopharmacol. 2012 Sep;27(5):239-48.

[2]. Endicott J, Sveds?ter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301-311.

[3]. Lee JG, Lee JI, Kim YT, Kim CE, Kim CY, Yoon JS, Yoo SY, Kim YH. Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia. Hum Psychopharmacol. 2012 Jul;27(4):403-10. doi: 10.1002/hup.2241.

[4]. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012 Jul;29(7):574-86. doi: 10.1002/da.21970.

[5]. Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C. Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients With Major Depressive Di

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
556.5ºC at 760 mmHg

[ Melting Point ]:
174-176°C

[ Molecular Formula ]:
C₂₃H₂₇N₃O₄S

[ Molecular Weight ]:
441.54

[ Flash Point ]:
290.4ºC

[ PSA ]:
221.80000

[ LogP ]:
4.04660

[ Vapour Pressure ]:
3.22E-13mmHg at 25°C

[ Storage condition ]:
-20°C Freezer

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07, GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H400

[ Precautionary Statements ]:
P273

[ Hazard Codes ]:
T,F

[ Risk Phrases ]:
R45:May cause cancer. R10:Flammable.

[ Safety Phrases ]:
S53-S45

[ RIDADR ]:
UN 3295 3/PG 3

[ WGK Germany ]:
3

[ RTECS ]:
PC1075000

[ Packaging Group ]:
III

[ Hazard Class ]:
3

[ HS Code ]:
2934999090

Customs

[ HS Code ]: 2934999090

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.

J. Neural Transm. Gen. Sect. 121(11) , 1337-47, (2014)

The dopaminergic stabilizers pridopidine [4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine] and ordopidine [1-ethyl-4-(2-fluoro-3-(methylsulfonyl)phenyl)piperidine] inhibit psychostimulant-induced hype...

An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - case study of multimodal characterization of quetiapine fumarate tablets.

Int. J. Pharm. 484(1-2) , 235-45, (2015)

Motivation for the study was the lack of dedicated and effective research and development (R&D) in vitro methods for oral, generic, modified release formulations. The purpose of the research was to as...

Quetiapine for the treatment of cocaine use disorder.

Drug Alcohol Depend. 149 , 18-24, (2015)

Cocaine addiction continues to be a significant healthcare issue, yet there are no FDA approved medications for the treatment of cocaine use disorder within the United States.This 12-week, prospective...